Innoviva price to free cash flow INVA

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: 7.9×
10-year median: 6.2×
Against its 10-year history: 75th; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.2× to 36.5×
Peer median: 8.9×

Innoviva's price to free cash flow is 7.9× as of Oct 23, 2026.

That is above its ten-year median of 6.2×, higher than on 75% of days in the last ten years.

Over that time it ranged from 2.2× in Sep 2022 to 36.5× in Oct 2016.

The median for 10 large drugmakers of a similar size is 8.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.9×	7.8×	8.1×
2025	5.8×	5.7×	7.2×
2024	6.8×	6.4×	9.1×
2023	8.8×	2.9×	10.0×
2022	3.2×	2.2×	4.0×
2021	3.4×	3.0×	4.4×
2020	4.3×	3.5×	4.3×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	17.3×	15.8×	28.1×
2016	25.0×	22.5×	155×

Against its peers

Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.

Company	Price to free cash flow
INVAInnoviva	7.9×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	8.1×
PAHCPhibro Animal Health	160×
ANIPANI Pharmaceuticals	9.6×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	7.0×
HRMYHarmony Biosciences	n/m
PBHPrestige Consumer Healthcare	9.6×
ABUSArbutus Biopharma	n/m
NRIXNurix Therapeutics	7.5×
Peer median	8.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Innoviva

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.